Panobinostat As Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects

Overview

Journal Oncol Ther

Specialty Oncology

Date 2017 Mar 7

PMID 28261641

Citations 17

Authors

Avineesh Singh

Vijay K Patel

Deepak K Jain

Preeti Patel

Harish Rajak

Affiliations

Soon will be listed here.

Abstract

The histone deacetylase (HDAC) inhibitors have been demonstrated as an emerging class of anticancer drugs. HDACs are involved in regulation of gene expression and in chromatin remodeling, thus indicating valid targets for different types of cancer therapeutics. The pan-deacetylase inhibitor panobinostat (Farydac, LBH589) was developed by Novartis Pharmaceuticals and has been recently approved by the US Food and Drug Administraion (FDA) as a drug to treat multiple myeloma. It is under clinical investigation for a range of haematological and solid tumors worldwide in both oral and intravenous formulations. Panobinostat inhibits tumor cell growth by interacting with acetylation of histones and non-histone proteins as well as various apoptotic, autophagy-mediated targets and various tumorogenesis pathways involved in development of tumors. The optimal combination regimen for pancreatic cancer remains to be fully elucidated with various combination regimens, and should be investigated in clinical trials. This article summarizes the current preclinical and clinical status of panobinostat in pancreatic cancer. Preclinical data suggests that panobinostat has potential inhibitory activity in pancreatic cancer cells by targeting various pathways and factors involved in the development of cancer. Herein, we reviewed the status of mono and combination therapy and the rationale behind the combination therapy undergoing trials, as well as possible future prospective use in the treatment of pancreatic cancer.

Citing Articles

Histone deacetylase inhibitors for leukemia treatment: current status and future directions.

Hosseini M, Sanaat Z, Akbarzadeh M, Vaez-Gharamaleki Y, Akbarzadeh M Eur J Med Res. 2024; 29(1):514.

PMID: 39456044 PMC: 11515273. DOI: 10.1186/s40001-024-02108-8.

Identifying drug candidates for pancreatic ductal adenocarcinoma based on integrative multiomics analysis.

Ge P, Wang Z, Wang W, Gao Z, Li D, Guo H J Gastrointest Oncol. 2024; 15(3):1265-1281.

PMID: 38989421 PMC: 11231868. DOI: 10.21037/jgo-23-985.

The Clinical Relevance of the EPH/Ephrin Signaling Pathway in Pediatric Solid and Hematologic Malignancies.

Chatzikalil E, Stergiou I, Papadakos S, Konstantinidis I, Theocharis S Int J Mol Sci. 2024; 25(7).

PMID: 38612645 PMC: 11011407. DOI: 10.3390/ijms25073834.

scDisInFact: disentangled learning for integration and prediction of multi-batch multi-condition single-cell RNA-sequencing data.

Zhang Z, Zhao X, Bindra M, Qiu P, Zhang X Nat Commun. 2024; 15(1):912.

PMID: 38291052 PMC: 10827746. DOI: 10.1038/s41467-024-45227-w.

Hsa_circRNA_001859 regulates pancreatic cancer progression and epithelial-mesenchymal transition through the miR-21-5p/SLC38A2 pathway.

Li L, Wang N, Wang J, Li J Cancer Biomark. 2023; 37(1):39-52.

PMID: 37005877 PMC: 10200212. DOI: 10.3233/CBM-220229.

References

Ungerstedt J, Sowa Y, Xu W, Shao Y, Dokmanovic M, Perez G . Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005; 102(3):673-8. PMC: 543461. DOI: 10.1073/pnas.0408732102. View

Garcia-Morales P, Gomez-Martinez A, Carrato A, Martinez-Lacaci I, Barbera V, Soto J . Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther. 2005; 4(8):1222-30. DOI: 10.1158/1535-7163.MCT-04-0186. View

Atadja P . Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009; 280(2):233-41. DOI: 10.1016/j.canlet.2009.02.019. View

Garnock-Jones K . Panobinostat: first global approval. Drugs. 2015; 75(6):695-704. DOI: 10.1007/s40265-015-0388-8. View

Schuettengruber B, Chourrout D, Vervoort M, LeBlanc B, Cavalli G . Genome regulation by polycomb and trithorax proteins. Cell. 2007; 128(4):735-45. DOI: 10.1016/j.cell.2007.02.009. View

Sharma S, Witteveen P, Lolkema M, Hess D, Gelderblom H, Hussain S . A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol. 2014; 75(1):87-95. DOI: 10.1007/s00280-014-2612-8. View

VAN Roy F, Berx G . The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008; 65(23):3756-88. PMC: 11131785. DOI: 10.1007/s00018-008-8281-1. View

Rajak H, Singh A, Raghuwanshi K, Kumar R, Dewangan P, Veerasamy R . A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity. Curr Med Chem. 2013; 21(23):2642-64. DOI: 10.2174/09298673113209990191. View

Sung V, Richard N, Brady H, Maier A, Kelter G, Heise C . Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells. Cancer Sci. 2011; 102(6):1201-7. DOI: 10.1111/j.1349-7006.2011.01921.x. View

10.

Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M . MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008; 12(12):2171-6. PMC: 4055565. DOI: 10.1007/s11605-008-0584-x. View

11.

Giver C, Jaye D, Waller E, Kaufman J, Lonial S . Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia. 2010; 25(2):362-5. DOI: 10.1038/leu.2010.262. View

12.

Cao K, Wang G, Li W, Zhang L, Wang R, Huang Y . Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene. 2015; 34(49):5960-70. PMC: 4672172. DOI: 10.1038/onc.2015.46. View

13.

Natoni F, Diolordi L, Santoni C, Gilardini Montani M . Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta. 2005; 1745(3):318-29. DOI: 10.1016/j.bbamcr.2005.07.003. View

14.

Marks P, Xu W . Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4):600-8. PMC: 2766855. DOI: 10.1002/jcb.22185. View

15.

Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F . Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29):26729-34. DOI: 10.1074/jbc.C500186200. View

16.

Singh B, Zhang G, Hwa Y, Li J, Dowdy S, Jiang S . Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther. 2010; 10(6):935-54. PMC: 3273412. DOI: 10.1586/era.10.62. View

17.

Wang G, He J, Zhao J, Yun W, Xie C, Taub J . Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One. 2012; 7(12):e52095. PMC: 3522644. DOI: 10.1371/journal.pone.0052095. View

18.

Birnbaum D, Mamessier E, Birnbaum D . The emerging role of the TGFβ tumor suppressor pathway in pancreatic cancer. Cell Cycle. 2012; 11(4):683-6. DOI: 10.4161/cc.11.4.19130. View

19.

Du Y, Liu M, Gao J, Li Z . Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation. Cancer Biother Radiopharm. 2013; 28(5):361-9. DOI: 10.1089/cbr.2012.1389. View

20.

Ougolkov A, Bilim V, Billadeau D . Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res. 2008; 14(21):6790-6. PMC: 2690708. DOI: 10.1158/1078-0432.CCR-08-1013. View